Showing results (301-310 of 351) with videos related to

Sort By:
Pageof 36
Antimicrobial Agents and Chemotherapy|June 10, 2015
Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with TuberculosisMarieke G G Sturkenboom, Leonie W Mulder, Arthur de Jager, et al.
Clinical Pharmacokinetics|April 19, 2019
Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with TuberculosisAntonia Morita I Saktiawati, Marcel Harkema, Althaf Setyawan, et al.
Plos Neglected Tropical Diseases|November 14, 2014
Persisting social participation restrictions among former Buruli ulcer patients in Ghana and BeninJanine de Zeeuw, Till F Omansen, Marlies Douwstra, et al.
Plos Neglected Tropical Diseases|October 29, 2019
Buruli ulcer treatment: Rate of surgical intervention differs highly between treatment centers in West AfricaAnita C Wadagni, Jonathan Steinhorst, Yves T Barogui, et al.
International Journal of Antimicrobial Agents|July 3, 2014
Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacinC Magis-Escurra, H M J Later-Nijland, J W C Alffenaar, et al.
Antimicrobial Agents and Chemotherapy|November 18, 2016
Low Caspofungin Exposure in Patients in Intensive Care UnitsKim C M van der Elst, Anette Veringa, Jan G Zijlstra, et al.
Emerging Infectious Diseases|June 5, 2003
Histopathologic features of Mycobacterium ulcerans infectionJeannette Guarner, Jeanine Bartlett, Ellen A Spotts Whitney, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2018
Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis PatientsM A Zuur, S Ghimire, M S Bolhuis, et al.
Medical Microbiology and Immunology|February 10, 2009
Buruli ulcer disease: prospects for a vaccineKris Huygen, Ohene Adjei, Dissou Affolabi, et al.
Pageof 36